全文获取类型
收费全文 | 3606篇 |
免费 | 181篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 135篇 |
妇产科学 | 61篇 |
基础医学 | 366篇 |
口腔科学 | 139篇 |
临床医学 | 267篇 |
内科学 | 924篇 |
皮肤病学 | 153篇 |
神经病学 | 306篇 |
特种医学 | 114篇 |
外国民族医学 | 1篇 |
外科学 | 515篇 |
综合类 | 36篇 |
预防医学 | 221篇 |
眼科学 | 40篇 |
药学 | 254篇 |
中国医学 | 13篇 |
肿瘤学 | 226篇 |
出版年
2023年 | 12篇 |
2022年 | 8篇 |
2021年 | 54篇 |
2020年 | 30篇 |
2019年 | 52篇 |
2018年 | 88篇 |
2017年 | 57篇 |
2016年 | 57篇 |
2015年 | 75篇 |
2014年 | 78篇 |
2013年 | 114篇 |
2012年 | 284篇 |
2011年 | 259篇 |
2010年 | 124篇 |
2009年 | 122篇 |
2008年 | 214篇 |
2007年 | 249篇 |
2006年 | 248篇 |
2005年 | 267篇 |
2004年 | 198篇 |
2003年 | 204篇 |
2002年 | 221篇 |
2001年 | 119篇 |
2000年 | 152篇 |
1999年 | 92篇 |
1998年 | 37篇 |
1997年 | 19篇 |
1996年 | 25篇 |
1995年 | 13篇 |
1994年 | 17篇 |
1993年 | 18篇 |
1992年 | 25篇 |
1991年 | 34篇 |
1990年 | 24篇 |
1989年 | 30篇 |
1988年 | 23篇 |
1987年 | 26篇 |
1986年 | 18篇 |
1985年 | 14篇 |
1984年 | 13篇 |
1983年 | 6篇 |
1982年 | 14篇 |
1980年 | 8篇 |
1978年 | 7篇 |
1977年 | 5篇 |
1976年 | 9篇 |
1974年 | 3篇 |
1971年 | 4篇 |
1968年 | 6篇 |
1965年 | 4篇 |
排序方式: 共有3798条查询结果,搜索用时 15 毫秒
71.
E Montserrat F Gomis T Vallespí A Ríos A Romero J Soler A Alcalá M Morey C Ferrán J Díaz-Mediavilla 《Blood》1991,78(6):1545-1551
We have analyzed 117 younger patients with chronic lymphocytic leukemia (CLL) (mean age, 44.5 years; SD, 4.8; range, 19 to 49; male/female ratio, 2.08) with three main objectives: (1) to see whether these patients have distinctive presenting clinical features; (2) to investigate the impact of the disease on survival; and (3) to analyze whether already well-known prognostic factors are also useful when applied to these patients. As compared with an older age population (greater than or equal to 50 years), there were no major differences in presenting features except for an increased proportion of males (2.08 v 1.21; P less than .025) and a higher hemoglobin level (13.47 +/- 2.70 g/dL v 12.84 +/- 2.77 g/dL; P less than .05) in the younger group. Median survival is 12.3 years (expected median from a control group, 31.2 years). Clinical stages, bone marrow patterns, blood lymphocyte counts, and its doubling time are all useful to separate different risk groups of patients. Whereas patients with favorable prognostic factors have a survival probability of about 80% 14 years after diagnosis, those with poor prognostic features have a median survival of less than 3 years. It is concluded that CLL in younger adults has no major distinctive presenting features and that known prognostic factors are useful to separate different risk groups of patients. These results should be of help in planning therapy for younger persons with CLL. 相似文献
72.
Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites 总被引:5,自引:0,他引:5
Bosch-Marcè M Clària J Titos E Masferrer JL Altuna R Poo JL Jiménez W Arroyo V Rivera F Rodés J 《Gastroenterology》1999,116(5):1167-1175
BACKGROUND & AIMS: The critical role of cyclooxygenase (COX) products in maintenance of renal function in cirrhosis with ascites discourages the use of nonsteroidal anti-inflammatory drugs in this disease. The recent development of selective COX-2 inhibitors opens new avenues for the use of these compounds in decompensated cirrhosis. The current study evaluates the effects of a selective COX-2 inhibitor (SC-236) on renal function in cirrhotic rats with ascites. METHODS: In protocol 1, urine volume, urinary excretion of sodium and prostaglandins, glomerular filtration rate, and renal plasma flow were measured before and after administration of SC-236 (n = 12) or ketorolac (n = 10) to rats with cirrhosis. Protocol 2 was aimed at assessing the effects of COX inhibitors on renal water metabolism in 28 cirrhotic rats. RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism. CONCLUSIONS: These findings indicate that SC-236 does not significantly impair renal function in rats with cirrhosis. 相似文献
73.
Ferrières J Elbaz M Maupas E Carriè D Puel J 《Archives des maladies du coeur et des vaisseaux》2004,97(3):187-193
The objective of this study was to compare the results of the management of dyslipidaemic patients in the community with the objectives fixed by the AFSSAPS recommendations. An observational epidemiological study was set up among 4 000 general practitioners and 527 cardiologists. This study included 22 323 patients (average age 60.6 years) affected by a documented primary dyslipidaemia. The average number of associated risk factors, according to the AFSSAPS criteria, was 1.8. The prevalence of secondary prevention in patients was 17.5%. More than 80% of patients were being treated by a lipid lowering agent (fibrate or statin) combined or not with lifestyle guidelines. In primary prevention, although the target levels of LDL-C fixed by the AFSSAPS were attained in 94.4% and 82.6% respectively for patients with no other risk factor or with one associated risk factor, the objectives were reached in only 55.4% of patients with two other risk factors and in 29.6% of patients with more than two other risk factors. In secondary prevention, the AFSSAPS objectives were attained in only 45.2% of patients. Following this lipid result, 34.8% of patients underwent therapeutic adjustment, principally the use of medication in the patients receiving lifestyle advice or reinforcement of pharmacological treatment. This study underlines the inadequate management in France of dyslipidaemic patients in the community. 相似文献
74.
75.
A Randomized, Controlled Study of Thymosin-α1 Therapy in Patients with Anti-HBe, HBV-DNA-Positive Chronic Hepatitis B 总被引:5,自引:0,他引:5
Zavaglia C Severini R Tinelli C Franzone JS Airoldi A Tempini S Bettale G Ideo G 《Digestive diseases and sciences》2000,45(4):690-696
No consistently effective therapy is yet available for the treatment of chronic HBsAg, anti-HBe, HBV-DNA-positive hepatitis. A multicenter trial has shown that the response rates are not significantly different when patients with anti-HBe-positive hepatitis are treated with six-month course of thymosin-1 or of interferon-. However, since among these patients, interferon's real efficacy is still debated, with sustained biochemical response achieved in only a few of the treated patients, we conducted this controlled study to investigate the safety and efficacy of thymosin-1 as compared with no treatment. Forty-four chronic hepatitis B virus (HBV) carriers, who were anti-HBe- and HBV-DNA-positive, were randomized, with stratification for the presence of cirrhosis at baseline liver biopsy, to receive either thymosin-1 at a dose of 900 g/m2 twice a week for six months or no treatment. At entry, both groups of patients were comparable for sex, age, liver histology, ALT, IgM anti-HBc, and HBV-DNA levels. Forty-two patients were followed-up for 20 months (median; range 12–32 months) after completion of therapy: one dropped out, and one developed hepatocellular carcinoma at six months. Thymosin-1 treatment had no side effects. Six months after the end of the therapy, HBV-DNA was negative and ALT had normalized in 14% of treated cases and in 4.5% of control group, while IgM anti-HBc was negative (<0.200) in 14% of the treated patients and in 4.5% of the controls. Among the treated patients, the median ALT levels stayed significantly lower compared to the pretreatment values during the treatment period and six months of follow-up. During the first year, there were six flares of hepatitis in the control group and five among the treated patients (P = NS), yielding a per year average of 0.3 and 0.23 flares per patient, respectively. Among the treated patients, median IgM anti-HBc levels were low with respect to baseline values 4–10 months after treatment started. None became HBsAg negative. In conclusion, these results indicate that, in anti-HBe, HBV-DNA-positive chronic hepatitis B, thymosin-1 therapy alone does not increase the response rate, but may contribute to reduce the immune-mediated liver cell necrosis as indirectly assessed by ALT and IgM anti-HBc levels. 相似文献
76.
PURPOSE OF REVIEW: Pulmonary arterial hypertension (PAH) is defined as a group of diseases characterized by a progressive increase of pulmonary vascular resistance leading to right ventricular failure and premature death. The purpose of this review is to analyze the current knowledge of the evaluation of PAH patients. RECENT FINDINGS: Recently, the diagnostic approach has been more clearly defined according to the new clinical classification and with consensus reached on algorithms of various investigative tests and procedures that exclude other causes and ensure an accurate diagnosis of PAH. The diagnostic procedures include clinical history and physical examination, ECG, chest radiography, transthoracic Doppler echocardiography, pulmonary function tests, arterial blood gases, ventilation and perfusion lung scan, high-resolution CT of the lung, contrast-enhanced spiral CT of the lung and pulmonary angiography, blood tests and immunology, abdominal ultrasound scan, exercise capacity assessment, and hemodynamic evaluation. SUMMARY: Invasive and noninvasive markers of disease severity, either biomarkers or physiologic parameters and tests that can be widely applied, have been proposed to reliably diagnose PAH and monitor the clinical course. 相似文献
77.
Danè Dabirrahmani Michael Christopher Hogg Peter Walker Daniel Biggs Ronald Mark Gillies 《Computers in biology and medicine》2013,43(12):2287-2296
Correct graft placement is critical to the success of anterior cruciate ligament reconstructions (ACLR). Whilst current trend is to insert the graft in an anatomical location, synthetic grafts have shown to better perform when they are located in an isometric position. Placement, however, is largely dependent on the surgeon and no consensus has been reached for synthetic grafts.Kinematic flexion-extension data of four separate cadaveric knees was obtained using an optical tracking system. Knees were CT-scanned and computer models were developed for each specimen. Three different graft insertion techniques were simulated in each of the computer models. Kinematic data obtained from the optical tracking was applied to the 3D computer models to simulate knee flexion-extension, and virtual change in ACL graft length was measured over the cycle for each insertion technique. Length changes were plotted onto the Radiological-Quadrant.The isometric region on the femur was found to be a band spreading from the mid to deep end of the Blumensaat's line down to the shallow-inferior end of the femoral condyle. The JP Laboureau isometric point technique was consistently located in the isometric zone, with the following coordinates on the Radiographic-Quadrant: t=0.375 (SD 0.0066), h=0.227 (SD 0.0266). The Bernard–Hertel and Charlie Brown anatomical placement methods were located (13%, ?6%) and (8%, ?15%) away, from the JP Laboureau isometric point, respectively, based on t- and h- coordinates of the Radiographic-Quadrant.This study has determined the isometric region using three-dimensional analysis relative to the Radiographic-Quadrant. The JP Laboureau method best finds the isometric point. This information is useful for synthetic graft placement. 相似文献
78.
Fernando J. Rascón-Ramírez Ángela María Carrascosa-Granada Andrés Camilo Vargas-Jiménez Borja Ferrández-Pujante Francisco Ortuño-Andériz 《Neurocirugía (Asturias, Spain)》2021,32(4):194-198
The coronavirus disease 2019 (COVID-19) has amazed by its distinct forms of presentation and severity.COVID-19 patients can develop large-scale ischemic strokes in previously healthy patients without risk factors, especially in patients who develop an acute respiratory distress syndrome (SARS-CoV-2).We hypothesize that ischemic events are usually the result of the combined process of a pro-inflammatory and pro-coagulant state plus vascular endothelial dysfunction probably potentiated by hypoxia, hemodynamic instability, and immobilization, as reported in other cases.To the best of our knowledge, we report the first case of partial obstruction of a vertebral artery in a patient with COVID-19.Decompressive surgery remains a life-saving maneuver in these patients (as in other non-COVID-19 strokes) and requires further investigation. 相似文献
79.
Gianfranco Mitacchione Marco Schiavone Antonio Curnis Marcello Arca Spinello Antinori Alessio Gasperetti Giosuè Mascioli Paolo Severino Federica Sabato Maria M. Caracciolo Gianmarco Arabia Laura D'Erasmo Maurizio Viecca Massimo Mancone Massimo Galli Giovanni B. Forleo 《Journal of clinical lipidology》2021,15(1):68-78
BackgroundEpidemiological evidence suggests that anti-inflammatory and immunomodulatory properties of statins may reduce the risk of infections and infection-related complications.ObjectiveWe aimed to assess the impact of prior statin use on coronavirus disease (COVID-19) severity and mortality.MethodsIn this observational multicenter study, consecutive patients hospitalized for COVID-19 were enrolled. In-hospital mortality and severity of COVID-19 assessed with National Early Warning Score (NEWS) were deemed primary and secondary outcomes, respectively. Propensity score (PS) matching was used to obtain balanced cohorts.ResultsAmong 842 patients enrolled, 179 (21%) were treated with statins before admission. Statin patients showed more comorbidities and more severe COVID-19 (NEWS 4 [IQR 2–6] vs 3 [IQR 2–5], p < 0.001). Despite having similar rates of intensive care unit admission, noninvasive ventilation, and mechanical ventilation, statin users appeared to show higher mortality rates. After balancing pre-existing relevant clinical conditions that could affect COVID-19 prognosis with PS matching, statin therapy confirmed its association with a more severe disease (NEWS ≥5 61% vs. 48%, p = 0.025) but not with in-hospital mortality (26% vs. 28%, p = 0.185). At univariate logistic regression analysis, statin use was confirmed not to be associated with mortality (OR 0.901; 95% CI: 0.537 to 1.51; p = 0.692) and to be associated with a more severe disease (NEWS≥5 OR 1.7; 95% CI 1.067–2.71; p = 0.026).ConclusionsOur results did not confirm the supposed favorable effects of statin therapy on COVID-19 outcomes. Conversely, they suggest that statin use should be considered as a proxy of underlying comorbidities, which indeed expose to increased risks of more severe COVID-19. 相似文献
80.
Ferré-Vallverdú Maria Sánchez-Lacuesta Elena Plaza-López Diego Díez-Gil José Luis Sepúlveda-Sanchis Pilar Gil-Cayuela Carolina Maceira-Gonzalez Alicia Miró-Palau Vicente Montero-Argudo Anastasio Martínez-Dolz Luis Igual-Muñoz Begoña 《The international journal of cardiovascular imaging》2021,37(5):1735-1744
The International Journal of Cardiovascular Imaging - Recent studies show that microvascular injury consists of microvascular obstruction (MVO) and intramyocardial hemorrhage (IMH). In patients... 相似文献